ProQR Therapeutics N.V. PRQR · Stock Open ProQR Therapeutics N.V. in new tab
Analyst price targets
Recent rating changes, newest first
ProQR Therapeutics N.V. Analysis (PRQR)
Is ProQR Therapeutics N.V. a good investment? ProQR Therapeutics N.V. (PRQR) is currently trading at 1.62 USD. Market analysts have a consensus price target of 7.78 USD. This suggests a potential upside from current levels.
Earnings Schedule: ProQR Therapeutics N.V. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.47.
Investor FAQ
Does ProQR Therapeutics N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.45.
Company Profile
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Community Discussion